In order to advance our innovative R&D pipeline we are continuously seeking new collaborations. We welcome licensing, partnering and alliances with leading players in the industry who can effectively contribute to bring novel melitherapy-based products to the market and make them available to patients globally.
We have recently joined the Growth segment of the Pre-Market Environment, in a step towards joining the stock market. The Pre-Market Environment (EpM) training program started in 2017 for growing SMEs. This ecosystem connects investors, companies and professionals from official and alternative markets of equities and bonds.
Welcome to our shareholder area. Here you will find updated information about the company’s stocks and finances. You can download and consult documents from shareholder meetings and agreements.
Would you like to become a shareholder in our company so we can establish melitherapy as a reference treatment globally? We are looking forward to working with private investors and institutions by joining the MAB stock market before the end of 2020.
We are also looking for partnering opportunities for our lead R&D program with LAM561A1 in oncology, which has just completed a P1/2a trial with excellent results. We are open to discussing global partnering opportunities as well as potential collaborations with strong and motivated local development and commercial partners in specific markets like Japan, China, South Korea, Russia, Europe, Mexico or North America, were we hold strong IP rights for this product. We are also considering partnering and investing opportunities for other melitherapy-based products in our pipeline, and particularly for our promising LAM226A1 program in Alzheimer’s disease.
If you are interested in investing or partnering opportunities, please contact us at firstname.lastname@example.org